Mantle Cell Lymphoma Medical Services in China

Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin lymphoma originating from B lymphocytes in the mantle zone of lymph nodes. Characterized by the t(11;14) chromosomal translocation leading to cyclin D1 overexpression, MCL typically presents in older adults with advanced-stage disease—often involving lymph nodes, bone marrow, gastrointestinal tract, and extranodal sites. Clinical behavior ranges from indolent to highly proliferative, with median overall survival historically around 5–7 years, though novel agents—including BTK inhibitors (e.g., ibrutinib, acalabrutinib), BCL-2 inhibitors (venetoclax), and chimeric antigen receptor T-cell (CAR-T) therapies—are significantly improving progression-free and overall survival. Accurate diagnosis requires integrated assessment: histopathology, immunohistochemistry (CD5+, CD20+, cyclin D1+), flow cytometry, and molecular testing (FISH for IGH-CCND1 fusion).

China offers compelling advantages for MCL management: leading oncology centers—such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center—house NMPA-approved CAR-T platforms (e.g., relmacabtagene autoleucel), next-generation sequencing for minimal residual disease monitoring, and multidisciplinary tumor boards with international training. Real-world data show comparable or superior response rates to global benchmarks, particularly in relapsed/refractory cases treated with domestically developed BTK inhibitors. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising protocol fidelity or supportive care standards.

As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with MCL-specialized hematologists, verifying treatment plans against NCCN/ESMO guidelines, providing itemized, upfront pricing, and managing visas, accommodation, translation, and post-treatment follow-up—all under one coordinated service.

Treatment Options & Itemized Cost Breakdown: Mantle Cell Lymphoma (MCL)

Non-Surgical / Systemic Therapy Options

*Eligibility*: Newly diagnosed, relapsed/refractory, or transplant-ineligible patients; confirmed by biopsy, flow cytometry (CD5+, CD20+, cyclin D1+), and FISH for *CCND1* translocation.

• •First-Line Chemoimmunotherapy (e.g., VR-CAP or BR)

- Rituximab + Bendamustine + Cytarabine (VR-CAP): ¥48,000–¥62,000/cycle × 6 cycles ($6,700–$8,700)

- Rituximab + Bendamustine (BR): ¥32,000–¥41,000/cycle × 6 cycles ($4,500–$5,700) - *Supportive labs per cycle*: CBC, LDH, renal/hepatic panel, β2-microglobulin — ¥420 ($60) - *Baseline diagnostics*: Bone marrow biopsy + aspirate, PET-CT, CT neck/chest/abdomen/pelvis — ¥12,800 ($1,800)

• •Targeted Therapy (BTK Inhibitors)

- Ibrutinib (oral, continuous): ¥19,200/month ($2,700/month)

- Acalabrutinib: ¥24,500/month ($3,400/month) - *Monitoring labs (q3mo)*: CBC, LFTs, coagulation panel — ¥380 ($55)

• •Maintenance Rituximab

- IV infusion q2mo × 2 years post-induction: ¥8,500/dose × 12 doses ($1,200/dose; total $14,400)

Surgical / Procedural Options

*Surgery is not curative but supports diagnosis/staging or manages complications.*

• •Diagnostic Lymph Node Biopsy (excisional)

- Eligibility: Suspected MCL with accessible node ≥1.5 cm; contraindicated in severe coagulopathy or uncontrolled infection.

- Procedure fee (Grade 3A hospital): ¥2,100–¥3,400 ($300–$480) - Pre-op workup (ECG, chest X-ray, PT/INR, platelets): ¥1,350 ($190)

• •Therapeutic Splenectomy (rare, for symptomatic hypersplenism or refractory cytopenias)

- Eligibility: Documented splenomegaly with transfusion-dependent cytopenias unresponsive to ≥2 systemic regimens.

- Laparoscopic procedure: ¥18,600–¥24,900 ($2,600–$3,500) - Pre-op: Enhanced CT abdomen, viral serologies, pneumococcal vaccination — ¥2,900 ($410)

Special/Complex Condition Management

• •Autologous Stem Cell Transplant (ASCT)

- Eligibility: Age ≤65, adequate cardiac/pulmonary/renal reserve, chemosensitive disease after induction.

- Total cost (mobilization, collection, conditioning [BEAM], infusion, 30-day monitoring): ¥142,000–¥178,000 ($19,900–$25,000)

• •CAR-T Therapy (e.g., Brexucabtagene autoleucel)

- Eligibility: Relapsed/refractory after ≥2 lines including BTKi and ASCT (or ineligible).

- Total (leukapheresis, manufacturing, infusion, 30-day toxicity management): ¥398,000–¥442,000 ($55,800–$62,000)

Quick Selection Guide

• •<60 years, fit, no comorbidities: BR → ASCT → Rituximab maintenance ($22,000–$32,000 total)
• •60–75 years, moderate comorbidities (e.g., hypertension, mild CKD): VR-CAP → maintenance ($28,000–$36,000)
• •>75 years or frail: BTK inhibitor monotherapy ($2,700–$3,400/month; median duration 24–36 mo)
• •Relapsed/refractory after BTKi + chemo: CAR-T if eligible ($55,800–$62,000 one-time)
• •Budget-constrained (<$15,000): BR regimen + supportive care ($4,500–$5,700/cycle × 6 = $27,000–$34,200; consider provincial insurance coverage reducing out-of-pocket to ~$6,000–$9,000)